PAMS
RVNC

Pictet Asset Management (Switzerland)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$228K Sell
8,991
-2,779
-24% -$86.6K ﹤0.01% 1655
2023
Q1 		$379K Buy
+11,770
New +$367K ﹤0.01% 1388

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RVNC Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Revance Therapeutics, Inc. (RVNC) stake by 24% in Q2 2023, selling an estimated $86.6K and leaving 8,991 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Pictet Asset Management (Switzerland) first reported a position in RVNC in Q1 2023 and has held it in 2 quarters since. The position peaked at $379K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 8,991 shares of Revance Therapeutics, Inc. worth $228K as of Q2 2023.
  • Pictet Asset Management (Switzerland) sold 2,779 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $86.6K.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1655 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Revance Therapeutics, Inc. in Q1 2023 and has held it in 2 quarters since.
  • Pictet Asset Management (Switzerland)'s Revance Therapeutics, Inc. position peaked at $379K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.